meso-1,2-bis(4-bromophenyl)-1,2-ethanediamine | 117903-53-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: meso-1,2-bis(4-bromophenyl)-1,2-ethanediamine
• 英文别名: 1,2-bis(4-bromophenyl)ethane-1,2-diamine；(1R,2S)-1,2-bis(4-bromophenyl)ethane-1,2-diamine
• CAS: 117903-53-4
• 化学式: C₁₄H₁₄Br₂N₂
• 分子量: 370.087
• InChiKey: XURRKKYAGFWNPT-OKILXGFUSA-N

物化性质

• 熔点：
  123-124 °C
• 沸点：
  464.1±40.0 °C(Predicted)
• 密度：
  1.650±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 安全说明：
  S45
• 危险类别码：
  R34

反应信息

• 作为反应物：
  描述：

  meso-1,2-bis(4-bromophenyl)-1,2-ethanediamine 在 4-二甲氨基吡啶 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 5.0h， 生成 2-(4-(4,5-bis(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydroimidazole-carbonyl)piperazinyl)ethyl 2-(tert-butoxycarbonylamino)acetate
  参考文献：
  名称：

  Synthesis and evaluation of an imidazole derivative–fluorescein conjugate

  摘要：

  The murine double minute (MDM2) oncogene a negative regulator of protein 53 (p53) tumor suppressor, is found overexpressed in many different types of cancer and the interaction between MDM2 and p53 has become the target of intensive research. MDM2 inhibitors represent a promising class of p53 activating compounds that may be effective in cancer treatment and diagnostic imaging. Nutlins, a family of cis-imidazoline analogues and small-molecule MDM2 antagonists, have the potential use in cancer therapies. We have synthesized an imidazole derivative (Nutlin-Glycine) conjugated to the commonly used fluorophore, 6-carboxyfluorescein (FAM) and evaluated its possible use as an imaging agent. Cellular uptake studies demonstrated that the fluorescence intensity in human osteosarcoma (SJSA-1) and colon carcinoma (HCT116) cells were significantly increased with the treatment of Nutlin-Glycine-FAM when compared with FAM (control). Blocking studies also confirmed that our imidazole-fluorescein conjugate may be a good candidate for imaging tumors, suggesting the need for further in vivo evaluation by positron emission tomography. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2012.11.026
• 作为产物：
  描述：

  4-bromo-N-(2-(4-bromobenzylideneamino)-1,2-(4-bromophenyl)ethyl)benzamide 在 硫酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 5.0h， 以66%的产率得到meso-1,2-bis(4-bromophenyl)-1,2-ethanediamine
  参考文献：
  名称：

  Synthesis and evaluation of an imidazole derivative–fluorescein conjugate

  摘要：

  The murine double minute (MDM2) oncogene a negative regulator of protein 53 (p53) tumor suppressor, is found overexpressed in many different types of cancer and the interaction between MDM2 and p53 has become the target of intensive research. MDM2 inhibitors represent a promising class of p53 activating compounds that may be effective in cancer treatment and diagnostic imaging. Nutlins, a family of cis-imidazoline analogues and small-molecule MDM2 antagonists, have the potential use in cancer therapies. We have synthesized an imidazole derivative (Nutlin-Glycine) conjugated to the commonly used fluorophore, 6-carboxyfluorescein (FAM) and evaluated its possible use as an imaging agent. Cellular uptake studies demonstrated that the fluorescence intensity in human osteosarcoma (SJSA-1) and colon carcinoma (HCT116) cells were significantly increased with the treatment of Nutlin-Glycine-FAM when compared with FAM (control). Blocking studies also confirmed that our imidazole-fluorescein conjugate may be a good candidate for imaging tumors, suggesting the need for further in vivo evaluation by positron emission tomography. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2012.11.026

文献信息

• [EN] NOVEL CIS-IMIDAZOLINES<br/>[FR] NOUVELLES CIS-IMIDAZOLINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005110996A1

  公开（公告）日：2005-11-24

  Formula (I) and the pharmaceutically acceptable salts and esters thereof, wherein X1, X2, X3,Y1, Y2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proiferative activity.

  公式（I）及其药用盐和酯，其中X1、X2、X3、Y1、Y2和R如本文所述，抑制MDM2蛋白与类p53肽的相互作用，从而具有抗增殖活性。
• [EN] CIS-IMIDAZOLINES AS MDM2 INHIBITORS<br/>[FR] CIS-IMIDAZOLINES INHIBITEURS DE MDM2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003051360A1

  公开（公告）日：2003-06-26

  The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity (I) (II).

  本发明提供了公式I和公式II的化合物及其药学上可接受的盐和酯，具有本文所提供的命名，并抑制MDM2蛋白与类p53肽的相互作用，并具有抗增殖活性。 (I)(II)。
• Chiral cis-imidazolines
  申请人：Fotouhi Nader

  公开号：US20050288287A1

  公开（公告）日：2005-12-29

  and the pharmaceutically acceptable salts and esters thereof, wherein X 1 , X 2 , X 3 , Y 1 , Y 2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.

  “and the pharmaceutically acceptable salts and esters thereof, wherein X1, X2, X3, Y1, Y2and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.” 翻译成中文为：“其中X1、X2、X3、Y1、Y2和R所描述的药物可接受的盐和酯类物质，能够抑制MDM2蛋白与p53样肽的相互作用，从而具有抗增殖活性。”
• CHIRAL CIS-IMIDAZOLINES
  申请人：Fotouhi Nader

  公开号：US20090143364A1

  公开（公告）日：2009-06-04

  and the pharmaceutically acceptable salts and esters thereof, wherein X 1 , X 2 , X 3 , Y 1 , Y 2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.

  本文中的药物可接受的盐和酯，其中X1、X2、X3、Y1、Y2和R的描述抑制MDM2蛋白与类p53肽的相互作用，因此具有抗增殖活性。
• Lipase-catalyzed desymmetrization of meso-1,2-diaryl-1,2-diaminoethanes
  作者：Daniel Méndez-Sánchez、Nicolás Ríos-Lombardía、Santiago García-Granda、José Montejo-Bernardo、Alfonso Fernández-González、Vicente Gotor、Vicente Gotor-Fernández

  DOI：10.1016/j.tetasy.2014.01.007

  日期：2014.2

  The synthesis and enzyme-catalyzed desymmetrization of meso-1,2-diaryl-1,2-diaminoethanes have been investigated. A family of aromatic meso-1,2-diamines, containing different substitution patterns in the aromatic ring, was first prepared and then desymmetrized enantioselectively using lipases as biocatalysts. Selective alkoxycarbonylation of one of the amino groups was achieved using allyl carbonates, isolating the corresponding allyl monocarbamates with moderate to high enantiomeric excess at 45 degrees C. Candida antarctica lipase types A (CAL-A) and B (CAL-B) displayed the best activities and stereopreferences, with a dramatic influence being observed depending on the diamine structure. Non substituted and para-substituted aryldiamines led to the formation of allyl carbamates with good enantiomeric excess, using CAL-A for the less hindered substrates and CAL-B for the more hindered ones. On the other hand meta- and ortho-derivatives afforded low or negligible conversions and selectivities, respectively. (C) 2014 Elsevier Ltd. All rights reserved.